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PLINICAL RESEARCH Interventional Cardiology
spirin and Clopidogrel Drug Response in
atients Undergoing Percutaneous Coronary Intervention
he Role of Dual Drug Resistance
li I. Lev, MD,* Rajnikant T. Patel, MD,* Kelly J. Maresh, RN, BSN,* Sasidhar Guthikonda, MD,*
uan Granada, MD,* Timothy DeLao, MLT,* Paul F. Bray, MD,† Neal S. Kleiman, MD*
ouston, Texas
OBJECTIVES We sought to evaluate the response to clopidogrel among aspirin-resistant versus aspirin-
sensitive patients undergoing percutaneous coronary intervention (PCI).
BACKGROUND Wide variability has been reported in response to aspirin and clopidogrel. There are limited
data on the simultaneous responses to both drugs.
METHODS Elective PCI patients (n  150) who received aspirin for 1 week but not clopidogrel were
included. All patients received bivalirudin during PCI. Blood samples were drawn at baseline
and 20 to 24 h after a 300-mg clopidogrel dose. Aspirin resistance was defined by 2 of 3
criteria: rapid platelet function analyzer-ASA score 550, 5 mol/l adenosine diphosphate
(ADP)-induced aggregation 70%, and 0.5 mg/ml arachidonic acid-induced aggregation
20%. Clopidogrel resistance was defined as baseline minus post-treatment aggregation
10% in response to 5 and 20 mol/l ADP.
RESULTS Nineteen (12.7%) patients were resistant to aspirin and 36 (24%) to clopidogrel. Nine (47.4%)
of the aspirin-resistant patients were also clopidogrel resistant. Aspirin-resistant patients were
more likely to be women and have diabetes than were aspirin-sensitive patients. They also had
lower response to clopidogrel, assessed by platelet aggregation and activation markers (flow
cytometry-determined PAC-1 binding and P-selectin expression). Elevation of creatine
kinase-myocardial band after stenting occurred more frequently in aspirin-resistant versus
aspirin-sensitive patients (38.9% vs. 18.3%; p  0.04) and in clopidogrel-resistant versus
clopidogrel-sensitive patients (32.4% vs. 17.3%; p  0.06).
CONCLUSIONS Aspirin-resistant patients as a group have reduced response to clopidogrel. Furthermore, we
have identified a unique group of dual drug-resistant patients who may be at increased risk for
thrombotic complications after PCI. (J Am Coll Cardiol 2006;47:27–33) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.058American College of Cardiology Foundation
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(spirin and clopidogrel have become standard therapy in
atients undergoing percutaneous coronary intervention
PCI) with stenting. However, there is considerable heter-
geneity in the responses of individual patients to each of
hese drugs (1–4). Previous studies have estimated that
dequate antiplatelet effects are not achieved in 5% to 45%
f patients taking aspirin and 4% to 30% of patients taking
lopidogrel (1,3–8).
Resistance to the antiplatelet effects of aspirin has been
ssociated with adverse clinical outcomes (2,5) and with an
ncrease in markers of myonecrosis following PCI (9). It has
een proposed that aspirin-resistant patients be treated
outinely with alternative antiplatelet drugs, mainly clopi-
ogrel. However, it is not clear whether the response to
lopidogrel is similar in aspirin-resistant and aspirin-
ensitive patients. Platelets from aspirin-resistant patients
ppear to have increased sensitivity to agonists such as
denosine diphosphate (ADP) and collagen (10,11). Fur-
From the *Cardiology Section, Methodist DeBakey Heart Center, and the
Thrombosis Research Section, Department of Medicine, Baylor College of Medi-
ine, Houston, Texas.P
Manuscript received June 17, 2005; revised manuscript received July 19, 2005,
ccepted August 2, 2005.hermore, aspirin resistance has been associated with plate-
et hyperreactivity (10,12). These hyperreactive platelets
ay also be less responsive to inhibition by other antiplate-
et drugs such as clopidogrel.
There are limited data regarding the simultaneous re-
ponses to both aspirin and clopidogrel. Lepantalo et al. (13)
ecently reported that among 50 patients undergoing PCI, 5
10%) were “poor responders” to both aspirin and clopi-
ogrel. Although this study is limited by the small number
f patients, it suggests that a subgroup of patients may have
ow response to both drugs. Our aim, therefore, was to
valuate prospectively the response to clopidogrel among
spirin-resistant versus aspirin-sensitive patients, and to
haracterize factors that affect the responses to either drug in
atients undergoing elective PCI.
ETHODS
atients. We enrolled patients scheduled for elective PCI
etween November 2003 and February 2005. All patients
ad received aspirin 81 to 325 mg daily for 1 week before
CI and had not received a thienopyridine or glycoprotein
GP) IIb/IIIa inhibitor in the week prior to enrollment.
atients were enrolled if they were planned to receive
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Low Response to Clopidogrel in Aspirin Resistance January 3, 2006:27–33ivalirudin rather than heparin and a GP IIb/IIIa inhibitor
uring PCI, because bivalirudin does not affect ADP-
nduced platelet aggregation (14). Exclusion criteria were
cute myocardial infarction (MI) within one week, any
ontraindications to aspirin, clopidogrel, or bivalirudin,
hrombocytopenia (100  103 cells/mm3), anemia (he-
oglobin 10 g/dl), or renal failure (creatinine 2.5
g/dl).
This study was approved by the Investigational Review
oard of the Baylor College of Medicine; all patients gave
nformed consent. Our aim was to enroll 150 patients. One
undred sixty patients were initially enrolled. Ten patients
eceiving GP IIb/IIIa inhibitors during PCI were with-
rawn from the study, leaving 150. All patients underwent
oronary stent implantation.
edications. Immediately following PCI all patients re-
eived 300 mg clopidogrel and 325 mg oral aspirin in the
atheterization laboratory under direct supervision, followed
y 75 mg clopidogrel and 325 mg aspirin daily thereafter.
uring PCI all patients received a standard course of
ntravenous bivalirudin bolus 0.75 mg/kg followed by an
nfusion of 1.75 mg/kg/h until PCI completion.
lood sampling. Two blood samples were collected in
ubes containing 3.2% citrate. The tubes were filled to
apacity and then gently mixed. The first (baseline) blood
ample was obtained in the catheterization laboratory, prior
o PCI and clopidogrel loading, from a 6- to 7-F arterial
heath. The second sample was obtained from an antecu-
ital vein, using a 21-gauge needle, 20 to 24 h after PCI.
lood samples were processed within 1 h of collection.
latelet aggregation. Turbidimetric platelet aggregation
as performed in platelet-rich plasma with a platelet count
djusted to 250  103/mm3. Platelets were stimulated with
.5 mg/ml (1.6 mmol/l) arachidonic acid (AA) and with 5
nd 20 mol/l ADP. Aggregation was performed with a
ioData PAP-4 platelet aggregometer (BioData, Horsham,
ennsylvania). The extent of aggregation was defined as the
aximal light transmission 6 min after addition of the
gonist, with platelet-poor plasma used as reference.
latelet activation. Platelet activation was determined by
ssessing platelet surface expression of activated GP IIb/IIIa
eceptors and P-selectin in response to ADP stimulation,
sing flow cytometry as previously described (15). Briefly,
Abbreviations and Acronyms
AA  arachidonic acid
ADP  adenosine diphosphate
ARU  aspirin reaction units
CK-MB  creatine kinase-myocardial band
GP  glycoprotein
MFI  mean fluorescence intensity
MI  myocardial infarction
PCI  percutaneous coronary intervention
RPFA-ASA  rapid platelet function assay-aspirinP IIb/IIIa activation was assessed using a fluorescein psothiocyanate-conjugated PAC-1 antibody (Becton Dick-
nson, San Jose, California), and P-selectin expression was
etermined using an R-phycoerythrin-conjugated anti-
D62P antibody (BD Pharmingen, San Jose, California).
itrated whole blood was diluted with Tyrode’s buffer and
timulated for 5 min with 10 mol/l ADP (final concen-
ration). After adding the corresponding antibody and
ncubating for 20 min, the mixture was fixated with
hosphate-buffered saline containing 1% paraformaldehyde.
amples were analyzed with a Coulter Epics XL MCL flow
ytometer (Beckman-Coulter, Miami, Florida). Non-
timulated samples served as negative controls. Both PAC-1
inding and P-selectin were expressed as log mean fluores-
ence intensity (MFI) and as percentage change in MFI
rom baseline to the post-PCI sample.
apid platelet function assay-aspirin (RPFA-ASA). A
oint-of-care system (VerifyNow; Accumetrics, San Diego,
alifornia), that uses cartridges containing fibrinogen-
oated beads and platelet agonists, RPFA-ASA measures
latelet agglutination in response to metallic cations and
ropyl gallate, which activate the cyclooxygenase-1 path-
ay. (The RPFA-ASA system we used differs from the
urrently available assay, which employs AA as the agonist.)
esults are expressed as aspirin reaction units (ARU). An
RU 550 indicates that aspirin-induced platelet dysfunc-
ion has not been detected (9).
arkers of myonecrosis. Creatine kinase-myocardial
and (CK-MB) levels were measured from frozen plasma
amples taken 20 to 24 h after PCI, using a sandwich
mmunoassay (Advia Centaur CKMB assay; Bayer Health-
are, Tarrytown, New York). Creatine-MB levels were
vailable for 144 patients. In all patients who had elevated
evels of CK-MB after PCI, normal CK-MB levels at
aseline were confirmed using the same assay. The upper
imit of normal for CK-MB is 5.0 ng/ml.
efinitions. Clopidogrel resistance was defined as an ab-
olute difference between baseline and post-treatment ag-
regation 10% in response to both 5 and 20 mol/l ADP
3,8). High post-clopidogrel platelet aggregation was de-
ned as 75th percentile aggregation in response to 5 and
0 mol/l ADP (16). The definition of aspirin resistance
as been less uniform (17). We employed a primary defi-
ition that incorporated previously used criteria (5,6,9) and
equired the presence of at least two of the following three:
) 0.5 mg/ml AA-induced platelet aggregation 20%; 2) 5
mol/l ADP-induced platelet aggregation 70%; and 3)
PFA-ASA ARU 550. To enable comparison with
revious studies, alternate analyses of the association be-
ween aspirin and clopidogrel response were performed
sing two additional definitions: 1) criteria 1 2 (5); and 2)
riterion 3 (9). Aspirin resistance was determined using the
aseline blood samples.
ample size and statistical analysis. The sample size was
redetermined based on logistic regression power analysis
ith a clopidogrel resistance rate of 30% used as the end
oint (3). Logistic regression of response to clopidogrel with
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January 3, 2006:27–33 Low Response to Clopidogrel in Aspirin Resistancesample size of 150 observations achieves 80% power at
.05 significance level to detect a change of 20% between
he two study groups (aspirin resistant vs. aspirin sensitive).
Continuous variables are presented as mean values  SD.
omparisons between continuous variables were performed
sing unpaired Student t tests, because they were normally
istributed (demonstrated by the Shapiro-Wilk test) (Fig. 1).
omparisons between categorical variables were performed
sing Fisher exact tests if any subgroups consisted of five or
ewer items; otherwise, chi-square tests were used. The
esponse to clopidogrel, expressed as change in platelet
ggregation or activation markers from baseline to post-
reatment, was compared among aspirin-resistant versus
igure 1. Distribution of the response to (A) aspirin (assessed by 0.5
g/ml arachidonic acid [AA]-induced platelet aggregation) and (B)
lopidogrel (evaluated by change in 5 mol/l adenosine diphosphate
ADP]-induced aggregation) from baseline to post-treatment. Both dis-
ributions were normal (p  0.0003 and p  0.01, respectively).
able 1. Rates of Clopidogrel Resistance in Aspirin-Resistant Ve
Aspirin Resistance Definition
ASA-Resistant
Patients (n)
Clopidogrel
Among ASA
Pati
t least 2 of the 3 criteria 19 9 (4
A aggregation 20% and
ADP aggregation 70%*
14 7 (5
PFA-ASA ARU 50 23 11 (40.5 mg/ml arachidonic acid-induced aggregation 20% and 5 mol/l ADP–induced aggr
ADP  adenosine diphosphate; ASA  aspirin; RPFA-ASA ARU  rapid platelet fuensitive patients using unpaired Student t tests. Two
urther analyses were performed. The response to clopi-
ogrel was compared among tertiles of AA-induced aggre-
ation using analysis of variance (ANOVA). In addition,
he percentages of patients with high post-clopidogrel
ggregation were compared with aspirin-resistant versus
spirin-sensitive patients. Analyses were performed using
PSS version 11 statistical software (SPSS Inc., Chicago,
llinois); statistical significance was set at p  0.05.
ESULTS
lopidogrel and aspirin resistance rates. Thirty-six pa-
ients (24%) met the definition of clopidogrel resistance.
spirin resistance was observed in 19 patients (12.7%) using
he primary definition (2 of the three criteria), 14 patients
9.3%) using the definition of AA-induced aggregation
20% and 5 mol/l ADP-induced aggregation 70%, and
3 patients (15.3%) with the definition of RPFA-ASA
RU 550 (Table 1). Regardless of which aspirin resis-
ance definition was used, about 50% of patients who were
spirin resistant were also resistant to clopidogrel, and about
0% of aspirin-sensitive patients were clopidogrel resistant
p  0.02) (Table 1). All subsequent comparisons between
spirin-resistant and aspirin-sensitive patients were per-
ormed using the primary definition.
To assess the role of prior medication compliance on
spirin resistance we compared AA-induced aggregation
efore and 20 to 24 h after the witnessed dose of aspirin.
here were no significant differences in AA-induced aggre-
ation between the two time points among aspirin-resistant
atients (pre-PCI 20.2  4.5% vs. post-PCI 18.8  2.9%;
 0.2) or among aspirin-sensitive patients (pre-PCI
0.5  4.7% vs. post-PCI 10  3.7%; p  0.3).
atient and procedural characteristics. Compared with
spirin-sensitive patients, aspirin-resistant patients were
ore likely to be women and to have diabetes (Table 2). Of
he 47 women, 11 (23.4%) were aspirin resistant compared
ith only 8 (7.8%) of the 103 men (p  0.01). Aspirin-
esistant patients also had lower hemoglobin levels than
spirin-sensitive patients. There were no differences in
atient characteristics between clopidogrel-resistant and
lopidogrel-sensitive patients (Table 2). We also compared
he characteristics of dual drug-resistant patients (resistant
o both aspirin and clopidogrel; n  9) to those of dual
Aspirin-Sensitive Patients
stance
sistant ASA-Sensitive
Patients (n)
Clopidogrel Resistance
Among ASA-Sensitive
Patients p Value
131 27 (20.6%) 0.01
136 29 (21.3%) 0.02
127 25 (19.7%) 0.01rsus
Resi
-Re
ents
7.4%)
0%)
7.8%)egation 70%.
nction assay-ASA expressed in aspirin reaction units.
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Low Response to Clopidogrel in Aspirin Resistance January 3, 2006:27–33rug-sensitive patients (n  104). Dual drug-resistant
atients were more likely to be women (67.7% vs. 26.9%;
 0.02) and had higher mean body mass index (33.8 
.9 kg/m2 vs. 29.7 5 kg/m2; p 0.03). Among the whole
tudy cohort, 60 (40%) patients were treated with 81 mg
spirin at the time of enrollment and 90 (60%) were treated
ith 325 mg. Ten (16.7%) of the 60 patients receiving 81
g were aspirin resistant, compared with 9 (10%) of the 90
atients receiving 325 mg (p  0.25).
There were no differences in indications for the PCI or
rocedural characteristics between aspirin-resistant and
spirin-sensitive patients or between clopidogrel-resistant
nd clopidogrel-sensitive patients (Table 3).
Table 2. Baseline Clinical Characteristics, Lab
Aspirin
Resistant
(n  19)
Age (yrs) 67.2  10.6
Women 11 (57.9%)*
BMI (kg/m2) 30.9  7.2
Diabetes 10 (52.6%)†
Hypertension 16 (84.2%)
Hyperlipidemia 16 (84.2%)
Smoking 7 (36.8%)
Prior MI 3 (15.8%)
Prior CABG 3 (15.8%)
Laboratory data
Hemoglobin (g/dl) 12.7  1.3*
WBC (103/mm3) 8.7  2.6
Platelets (103/mm3) 236.9  71
Mean platelet volume (fl) 9.8  1.6
Creatinine (mg/dl) 1.2  0.4
Baseline medications
Aspirin 81 mg 10 (52.6%)
Aspirin 325 mg 9 (47.4%)
Statins 16 (84.2%)
Beta-blockers 14 (73.7%)
ACEI/ARB 6 (31.6%)
CCB 3 (15.8%)
*p  0.01; †p  0.05; for aspirin resistance vs. aspirin sensi
ACEI angiotensin-converting enzyme inhibitors; ARB
 coronary artery bypass graft; CCB  calcium channel blo
WBC  white blood cells.
Table 3. Indications for Percutaneous Coronar
Aspirin
Resistant
(n  19)
Indication
Stable angina 10 (52.6%)
Unstable angina 4 (21.1%)
NSTEMI 1 week 3 (15.8%)
() Stress test 4 (21.1%)
Procedural characteristics
Total stent length (mm) 22.6  9.3
Minimal stent diameter (mm) 3.0  0.6
No. of stents/patient 1.4  0.6
Drug-eluting stents 15 (78.9%)
Bare-metal stents 4 (21.1%)NSTEMI  non–ST-segment elevation myocardial infarction; (esponse to clopidogrel among aspirin-resistant versus
sensitive patients. Aspirin-resistant patients had a signifi-
antly lower degree of reduction of platelet aggregation in
esponse to 5 and 20 mol/l ADP after clopidogrel (Table 4).
hey also displayed less inhibition of PAC-1 binding and a
ower degree of reduction in P-selectin expression after
lopidogrel treatment (Table 4).
The percentage of patients with high post-clopidogrel
DP-induced aggregation (75th percentile) was higher
mong aspirin-resistant than aspirin-sensitive patients (5
mol/l ADP: 78.9% vs. 18.3%, p 0.001; 20 mol/l ADP:
3.4% vs. 19.1%, p  0.001). Furthermore, comparison of
he change in ADP-induced aggregation among tertiles
ry Data, and Medications
Aspirin
Sensitive
(n  131)
Clopidogrel
Resistant
(n  36)
Clopidogrel
Sensitive
(n  114)
5.3  10.6 64.3  10.1 65.9  11.3
6 (27.5%)* 15 (41.7%) 32 (28.1%)
9.8  5 31.3  6 29.4  5
8 (29%)† 12 (33.3%) 36 (31.6%)
0 (84%) 30 (83.3%) 96 (84.2%)
1 (69.5%) 26 (72.2%) 81 (71.1%)
2 (32.1%) 11 (30.6%) 38 (33.3%)
6 (19.8%) 9 (25%) 20 (17.5%)
8 (21.4%) 8 (22.2%) 23 (20.2%)
3.9  1.6* 13.6  1.8 13.8  1.5
7.4  2.4 8.2  2.5 7.3  2.4
4.8  62 218.4  64 204.9  62.8
9.4  1.2 9.9  1.5 9.3  1.4
1.1  0.3 1.1  0.3 1.2  0.3
0 (38.2%) 15 (41.7%) 45 (39.5%)
1 (61.8%) 21 (58.3%) 69 (60.5%)
2 (70.2%) 28 (77.8%) 80 (70.2%)
2 (55%) 25 (69.4%) 61 (53.5%)
0 (38.2%) 9 (25%) 47 (41.2%)
6 (19.8%) 5 (13.9%) 24 (21.1%)
iotensin receptor blockers; BMI body mass index; CABG
MI  myocardial infarction; Smoking  current or former;
ervention and Procedural Characteristics
Aspirin
Sensitive
(n  131)
Clopidogrel
Resistant
(n  36)
Clopidogrel
Sensitive
(n  114)
55 (42%) 19 (52.8%) 46 (40.4%)
34 (26%) 8 (22.2%) 30 (26.3%)
11 (8.4%) 2 (5.6%) 12 (10.5%)
46 (35.7%) 12 (33.3%) 38 (33.3%)
21.2  9.9 23.5  11 20.7  9.4
3.0  0.4 3.0  0.5 3.0  0.4
1.3  0.6 1.5  0.7 1.3  0.5
117 (89.3%) 31 (86.1%) 100 (87.7%)
14 (10.7%) 5 (13.9%) 14 (12.3%)orato
6
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2
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2
tivity.
 angy Int) Stress test  positive stress test.
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January 3, 2006:27–33 Low Response to Clopidogrel in Aspirin Resistancef AA-induced aggregation revealed a significant differ-
nce between the tertiles (5 mol/l ADP, p  0.006; 20
mol/l ADP, p  0.0001) (Fig. 2). Patients in the
ighest tertile (reflecting lower response to aspirin) had
he least reduction in ADP-induced aggregation after
lopidogrel treatment.
Comparison of baseline platelet reactivity showed a trend
oward higher baseline P-selectin levels among aspirin-
esistant versus aspirin-sensitive patients (15.6  5.1 MFI
s. 13.8  4.2 MFI; p  0.1).
arkers of myonecrosis. Levels of CK-MB post-PCI
ere available for 144 patients. Thirty (20.8%) of the 144
atients had CK-MB levels above the upper limit of normal
Fig. 3). Elevation of CK-MB occurred more frequently in
Table 4. Response to Clopidogrel Among Asp
Absolute change in 20 mol/l ADP aggregation (%)
Absolute change in 5 mol/l ADP aggregation (%)
Absolute change in PAC-1 binding (MFI)
Absolute change in P-selectin expression (MFI)
Relative change in PAC-1 binding (%)
Relative change in P-selectin expression (%)
Absolute change  absolute difference between baseline and
from baseline.
ADP  adenosine diphosphate; MFI  mean fluorescen
igure 2. Response to clopidogrel among the three tertiles of 0.5 mg/ml
rachidonic acid (AA)-induced aggregation (reflecting response to aspirin).
ggregation in response to (A) 5 mol/l and (B) 20 mol/l adenosine
iphosphate (ADP) (p 0.006 and p 0.0001, respectively, for difference
etween tertiles).
a
pspirin-resistant than in aspirin-sensitive patients (38.9% vs.
8.3%; p  0.04) and in dual drug-resistant than in dual
rug-sensitive patients (44.4% vs. 15.8%; p  0.05). There
as also a trend toward more frequent CK-MB elevations
mong clopidogrel-resistant versus clopidogrel-sensitive pa-
ients (32.4% vs. 17.3%; p  0.06).
ISCUSSION
his is the first study to characterize the response to
lopidogrel among aspirin-resistant compared with aspirin-
ensitive patients. It is also the first study of antiplatelet drug
esponse to be performed in the presence of a direct
hrombin inhibitor rather than unfractionated heparin, in
rder to avoid the confounding effects of heparin on platelet
ctivity. We observed aspirin resistance in 9% to 15% of
atients, depending on the definition used, and clopidogrel
esistance in 24%. About one-half of the aspirin-resistant
atients were also resistant to the effects of clopidogrel.
urthermore, we have shown that aspirin-resistant patients
s a group display a lower inhibitory response to clopidogrel
han aspirin-sensitive patients.
linical factors associated with drug resistance. Our
econdary objective was to identify clinical factors associated
ith low response to aspirin or clopidogrel. Aspirin-
esistant and dual drug-resistant patients were more likely to
e women compared with aspirin-sensitive and dual drug-
ensitive patients. This finding is in accordance with the
tudies of Gum et al. (5) and Chen et al. (9), who also found
higher proportion of women among aspirin-resistant
Resistant Versus Aspirin-Sensitive Patients
spirin Resistant
(n  19)
Aspirin Sensitive
(n  131) p Value
8.3  7.3 15.0  10.2 0.001
13.8  9.7 20.6  12.5 0.01
0.8  1.5 1.7  1.2 0.01
4.1  3.4 5.6  3.5 0.09
14.6  25.6 35  24.1 0.002
25.9  23.8 40.4  21.8 0.02
reatment aggregation; relative change  percentage decrease
ensity.
igure 3. Incidence of creatinine kinase-myocardial band (CK-MB) ele-
ation above the upper limit of normal in aspirin (ASA)-resistant versusirin-
A
post-tspirin-sensitive patients, clopidogrel-resistant versus clopidogrel-sensitive
atients, and dual drug-resistant versus dual drug-sensitive patients.
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Low Response to Clopidogrel in Aspirin Resistance January 3, 2006:27–33atients. The greater proportion of women may explain the
ower hemoglobin level we observed among aspirin-resistant
ompared with aspirin-sensitive patients. The consistently
igher rates of aspirin resistance among women may also
ccount in part for the recently reported failure of aspirin to
educe the risk of a first MI in women, in contrast to its
eneficial primary prevention effects in men (18).
An additional clinical factor we found to be associated
ith aspirin resistance is diabetes. Platelets from individuals
ith type 2 diabetes have been shown to have a reduced
esponse to aspirin (19). Furthermore, obesity and insulin
esistance have been associated with impaired platelet-
nhibitory effects of aspirin in non-diabetic patients (20).
his association may explain the significantly elevated BMI
e observed in the dual drug-resistant group in our study.
epantalo et al. (13) reported that low response to clopi-
ogrel was associated with high levels of glycosylated
emoglobin and C-peptide. Therefore, insulin resistance
ay be associated with reduced response to both drugs.
ossible mechanisms for dual drug resistance. There are
everal plausible explanations for our findings of lower
esponse to clopidogrel among aspirin-resistant patients as a
roup. The most likely mechanism is a global increase in
latelet reactivity. Platelets from aspirin-resistant patients
ppear to have increased sensitivity to ADP-induced GP
Ib/IIIa activation (10) as well as to low concentrations of
ollagen (11). Furthermore, patients with diabetes, who
omprised more than half of the aspirin-resistant group,
ave been shown to have a higher proportion of platelets
xpressing P-selectin and activated GP IIb/IIIa receptors
han non-diabetic patients (21,22). Although we observed
nly a trend toward higher baseline P-selectin expression in
spirin-resistant patients, if indeed these patients have
yper-reactive platelets they may be less sensitive to inhibi-
ion by clopidogrel.
Two other mechanisms are also possible. First, increased
latelet turnover in aspirin-resistant patients may lead to the
elease of young platelets still able to form thromboxane A2
hrough non-cyclooxygenase-1–dependent pathways and
espond to ADP despite aspirin and clopidogrel treatment.
e did not, however, observe differences in the mean
latelet volume, which may reflect platelet age, between the
ifferent groups in our study. Second is poor compliance.
his is unlikely, however, because the clopidogrel loading
ose as well as an aspirin dose were administered in the
atheterization laboratory under direct supervision. The
econd blood sample was drawn 20 to 24 h after this
reatment, and there were no differences in AA-induced
latelet aggregation between the baseline and post-
reatment samples.
linical importance. Our study extends previous findings
f an association between adverse clinical events and resis-
ance to aspirin (2,5,9) or clopidogrel (23). We evaluated the
ncidence of CK-MB elevation following PCI, which has
een consistently shown to be associated with higher risk of
eath, MI, and repeat revascularization (24). In accordance Mith the report by Chen et al. (9), we have found that
spirin-resistant patients had a more than two-fold increase in
he incidence of myonecrosis following PCI. Clopidogrel-
esistant patients also tended to have more frequent CK-MB
levation compared with clopidogrel-sensitive patients, con-
rming recent clinical reports (23). Dual drug-resistant
atients also had a more than two-fold increase in the rate
f myonecrosis compared with dual drug-sensitive patients.
his finding supports the recent case-control observation by
enaweser et al. (25) that among 23 patients with previous
tent thrombosis, about half were resistant to the effects of
oth aspirin and clopidogrel. Taken together, these findings
hould raise a note of caution that a modest proportion of
atients undergoing high-risk PCI may not have adequate
ntithrombotic protection despite dual antiplatelet therapy.
tudy limitations. Our study has several limitations. First,
t was powered to evaluate differences in the response to
lopidogrel among aspirin-resistant versus aspirin-sensitive
atients. However, the sample size was inadequate to
stimate the risk of myonecrosis associated with dual drug
esistance. Second, the antiplatelet effects of aspirin and
lopidogrel were evaluated at two points during a single
4-h period and may not reflect possible temporal fluctua-
ions in individual responses. Nevertheless, these measure-
ents reflect the extent of platelet inhibition just before and
ollowing PCI, when optimal inhibition is required. Third,
he first blood sample was drawn from an arterial access and
he second from a venous access. These conditions were,
owever, identical for both groups tested. Finally, our study
as performed with a clopidogrel loading dose of 300 mg.
ecent studies have indicated that a loading dose of 600
g provides a more rapid and pronounced early response
nd reduces the rate of clopidogrel resistance (16,26,27).
owever, most clinical efficacy data have been accrued
ith the 300 mg dose, and this is the only dose that is
urrently approved by the U.S. Food and Drug Admin-
stration (28).
onclusions. We have identified a unique group of dual
rug-resistant patients who do not achieve adequate anti-
latelet effects from either aspirin or clopidogrel. The
elatively high incidence of CK-MB elevation after PCI in
hese patients suggests that they may be at high risk for
hrombotic complications following coronary intervention.
his finding should be confirmed in a larger-scale study.
evertheless, the lower response to clopidogrel among
spirin-resistant patients is of particular clinical importance,
ecause clopidogrel has been suggested as alternative therapy
or aspirin-resistant patients. Our data would imply that this
pproach may not be sufficient and that other platelet inhibi-
ors acting on additional targets (other than cyclooxygenase-1
nd P2Y12) should be developed and investigated.
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